40384111000001100: Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd) (product)

SNOMED CT Concept\Pharmaceutical / biologic product\...

\UK product\Actual medicinal product\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\UK product\Virtual medicinal product\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\UK product\Virtual therapeutic moiety\Amivantamab\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\UK product\Trade family\Rybrevant\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)

\Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing amivantamab (medicinal product)\Amivantamab\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Product containing protein-tyrosine kinase inhibitor\Product containing amivantamab (medicinal product)\Amivantamab\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\Medicinal product\Medicinal product categorized by structure\Product containing nitrogen and/or nitrogen compound (product)\Product containing polypeptide\Product containing protein\Product containing antibody\Product containing monoclonal antibody\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing amivantamab (medicinal product)\Amivantamab\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing amivantamab (medicinal product)\Amivantamab\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing amivantamab (medicinal product)\Amivantamab\Amivantamab 350mg/7ml solution for infusion vials\Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 19-Jan 2022. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module

1915361000001119 Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

1915371000001112 Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has specific active ingredient	Amivantamab	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has excipient	Excipient not declared	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator	NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has excipient	Edetic acid	false	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Is a	Actual medicinal product	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator	EMA (European Medicines Agency) monitoring	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Is a	Amivantamab 350mg/7ml solution for infusion vials	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has excipient	Polysorbate	false	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Is a	Rybrevant	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has NHS dm+d (dictionary of medicines and devices) controlled drug category	Controlled drug category No Controlled Drug Status	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	VMP non-availability indicator	Available	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has specific active ingredient	Amivantamab	false	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has dispensed dose form	Conventional release solution for infusion	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	VMP prescribing status (attribute)	VMP valid as a prescribable product	true	Inferred relationship	Existential restriction modifier
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Has excipient	Edetic acid	true	Inferred relationship	Existential restriction modifier

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd) 1 vial	Has AMP	True	Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	Inferred relationship	Existential restriction modifier

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
1915361000001119	Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd)	en	Synonym	Active	Entire term case sensitive	SNOMED CT United Kingdom drug extension module
1915371000001112	Rybrevant 350mg/7ml concentrate for solution for infusion vials (Janssen-Cilag Ltd) (product)	en	Fully specified name	Active	Entire term case sensitive	SNOMED CT United Kingdom drug extension module